NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
Clinical Trials
7 trialsNCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT01413451 2019-12-17
Amatuximab for High Mesothelin Cancers
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Terminated
NCT01521325 2016-09-30
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Morphotek
Phase 1 Completed
NCT01018784 2016-01-21
A Study of MORAb-009 in Patients With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT00570713 2015-09-09
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
Morphotek
Phase 2 Completed
NCT00325494 2014-07-17
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Morphotek
Phase 1 Completed